Lung cancer is the leading cause of cancer-related deaths, and the most common form is a non-small-cell type called adenocarcinoma.
The main course of treatment today, a kinase inhibitor drug called Osimertinib, is effective for many adenocarcinoma patients. However, after a year or more, the cancer usually develops resistance to the drug, and the tumor can regrow.
